Cytotoxic Drugs Global Market Report 2024

The cytotoxic drugs market size has grown strongly in recent years. It will grow from $14.54 billion in 2023 to $15.35 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth observed in the historical period can be attributed to several factors, including the global rise in cancer prevalence, increased healthcare expenditure, the growth of the aging population, availability of government funding and grants, and heightened public awareness about cancer treatments.

The cytotoxic drugs market size is expected to see strong growth in the next few years. It will grow to $19.21 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The projected growth in the forecast period is expected to be driven by factors such as the adoption of personalized medicine approaches, expansion of specialized cancer treatment centers, increasing incidence of cancer attributed to lifestyle changes, rising demand for combination therapies, and government initiatives supporting cancer treatment and research. Significant trends anticipated for this period encompass a shift towards targeted therapies over traditional chemotherapy, the increasing utilization of biologics and biosimilars in cancer treatment, integration of artificial intelligence in drug discovery and development processes, and a rise in collaborations between biotech firms and academic institutions.

The rising occurrence of target diseases is expected to drive the growth of the cytotoxic drugs market in the coming years. Target diseases refer to specific illnesses or conditions that are the focus of concentrated medical research, treatment, or intervention efforts aimed at improving patient outcomes. Examples of target diseases include cancer, autoimmune disorders, genetic conditions, and others. Factors contributing to the increased incidence of target diseases include genetic predisposition, environmental factors, and inadequate access to healthcare. Cytotoxic drugs play a crucial role in combating the increased occurrence of target diseases by either killing or inhibiting the growth of disease-causing cells, thereby curbing their proliferation and spread. For example, data published by the International Agency for Research on Cancer (IARC), a specialized cancer agency of the World Health Organization (WHO), revealed approximately 20 million new cancer cases and 9.7 million deaths worldwide in 2022. Projections suggest a staggering 77% increase to over 35 million new cases by 2050. Notably, lung cancer and female breast cancer were the most prevalent globally in 2022. Hence, the heightened occurrence of target diseases is a driving force behind the expansion of the cytotoxic drugs market.

Key players in the cytotoxic drugs market are intensifying their efforts to develop advanced and innovative solutions, such as chimeric antigen receptor (CAR) T cell therapies, to offer transformative treatment options for patients with specific types of blood cancer. CAR T cell therapy represents a pioneering treatment approach that employs genetically engineered T cells to combat cancer cells, marking a significant breakthrough in oncology therapeutics. For instance, in March 2024, Bristol Myers Squibb announced FDA approval of Breyanzi, a CD19-directed CAR T cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval underscores the advancements in personalized medicine through CD19-directed CAR T cell therapy, providing new treatment avenues and improved efficacy for patients.

In March 2024, Johnson & Johnson acquired Ambrx Biopharma Inc. for approximately $2 billion, enhancing its oncology portfolio and prostate cancer innovation by leveraging Ambrx's advanced ADC (antibody-drug conjugate) technology. This technology combines specific monoclonal antibodies with potent chemotherapeutic payloads, augmenting Johnson & Johnson's capabilities in manufacturing cytotoxic drugs. Ambrx Biopharma Inc., a clinical-stage biopharmaceutical company based in the US, specializes in the development of cytotoxic drugs.

Major companies operating in the cytotoxic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Fresenius Kabi AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Daiichi Sankyo Company Limited, Lonza, Eisai Co. Ltd., Sun Pharmaceuticals, Sumitomo Dainippon Pharma, Jazz Pharma, Ipsen Pharma, Kyowa Kirin Co. Ltd., Cipla Ltd., Mallinckrodt Pharmaceuticals, Hansoh Pharmaceutical Group Company Limited, Piramal Group.

North America was the largest region in the cytotoxic drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cytotoxic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cytotoxic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cytotoxic drugs constitute a class of medications designed to halt or eradicate rapidly proliferating cells, particularly cancer cells, by impeding their growth and division. They accomplish this by disrupting various biological processes, including metabolism, mitosis, and DNA replication. These drugs are frequently administered in conjunction with other therapeutic modalities such as surgery, radiation therapy, and targeted therapies to maximize treatment effectiveness and better manage cancer.

The primary types of cytotoxic drugs include alkylating agents, antitumor antibiotics, antimetabolites, plant alkaloids, and others. Alkylating agents, for instance, are utilized in cancer treatment to induce DNA damage in cancer cells, thus inhibiting their ability to multiply. These drugs find application across various therapies such as chemotherapy, radiotherapy, immunotherapy, and stem cell transplantation, addressing conditions such as oncology, rheumatoid arthritis, multiple sclerosis, among others. They are utilized by a diverse range of end users including hospitals, cancer research centers, drug testing laboratories, and contract development and manufacturing organizations (CDMOs).

The cytotoxic drugs market research report is one of a series of new reports that provides cytotoxic drugs market statistics, including cytotoxic drugs industry global market size, regional shares, competitors with a cytotoxic drugs market share, detailed cytotoxic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cytotoxic drugs industry. This cytotoxic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cytotoxic drugs market consists of sales of monoclonal antibodies, tyrosine kinase inhibitors, topoisomerase inhibitors, platinum-based drugs, proteasome inhibitors, and angiogenesis inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.